Cencora Management

Management criteria checks 3/4

Cencora's CEO is Steve Collis, appointed in Nov 2010, has a tenure of 13.42 years. total yearly compensation is $17.51M, comprised of 8% salary and 92% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $68.67M. The average tenure of the management team and the board of directors is 5.3 years and 8.9 years respectively.

Key information

Steve Collis

Chief executive officer

US$17.5m

Total compensation

CEO salary percentage	8.0%
CEO tenure	13.4yrs
CEO ownership	0.1%
Management average tenure	5.3yrs
Board average tenure	8.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Collis's remuneration changed compared to Cencora's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$18m	US$1m	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$15m	US$1m	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$14m	US$1m	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$11m	US$1m	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$12m	US$1m	US$2b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$855m
Dec 31 2017	n/a	n/a	US$979m
Sep 30 2017	US$10m	US$1m	US$364m

Compensation vs Market: Steve's total compensation ($USD17.51M) is above average for companies of similar size in the UK market ($USD5.62M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Collis (62 yo)

13.4yrs

Tenure

US$17,511,240

Compensation

Mr. Steven H. Collis, also known as Steve, has been the Chief Executive Officer and President of Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since July 2011 and November 2010 respective...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Collis	Chairman	13.4yrs	US$17.51m	0.14% $ 68.7m
James Cleary	Executive VP & CFO	5.4yrs	US$5.45m	0.057% $ 27.5m
Robert Mauch	Executive VP & COO	1.5yrs	US$7.70m	0.012% $ 5.9m
Gina Clark	Executive VP and Chief Communications & Administration Officer	6.8yrs	US$3.17m	0.012% $ 6.0m
Elizabeth Campbell	Executive VP & Chief Legal Officer	2.6yrs	US$4.03m	0.0041% $ 2.0m
Lazarus Krikorian	Senior VP	12.3yrs	no data	0.010% $ 4.8m
Bennett Murphy	Senior Vice President of Investor Relations	no data	no data	no data
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	no data	no data
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.3yrs	US$3.48m	0.0062% $ 3.0m
Leslie Donato	Executive VP & Chief Strategy Officer	4.8yrs	no data	0.0043% $ 2.1m
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.3yrs	no data	no data
J. Quinn	VP & Corporate Treasurer	no data	no data	no data

5.3yrs

Average Tenure

57yo

Average Age

Experienced Management: 0HF3's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Collis	Chairman	12.9yrs	US$17.51m	0.14% $ 68.7m
Lauren Tyler	Independent Director	less than a year	no data	no data
Richard Gochnauer	Independent Director	15.6yrs	US$300.10k	0.011% $ 5.4m
Mark M. Durcan	Lead Independent Director	8.6yrs	US$380.05k	0.0081% $ 3.9m
Lon Greenberg	Independent Director	10.9yrs	US$332.60k	0.0092% $ 4.4m
Kathleen Hyle	Independent Director	13.9yrs	US$320.10k	0.011% $ 5.1m
Dennis Nally	Independent Director	4.3yrs	US$375.36k	0.0042% $ 2.0m
Ornella Barra	Director	9.3yrs	no data	0% $ 0
Henry McGee	Independent Director	19.4yrs	US$320.10k	0.0075% $ 3.6m
Werner Baumann	Independent Director	less than a year	no data	no data
Lorence Kim	Independent director	1.5yrs	US$397.33k	0.000080% $ 38.4k
Redonda Miller	Independent Director	1.3yrs	US$311.82k	0.00078% $ 374.4k

8.9yrs

Average Tenure

63yo

Average Age

Experienced Board: 0HF3's board of directors are considered experienced (8.9 years average tenure).

Cencora Management

Management criteria checks 3/4

Key information

Recent management updates

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Chairman recently sold US$8.7m worth of stock

Insider recently sold US$2.0m worth of stock

Recent updates

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

First quarter dividend of US$0.51 announced

First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Chairman recently sold US$8.7m worth of stock

Now 20% undervalued

Insider recently sold US$2.0m worth of stock

Now 21% undervalued

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022)

Now 20% undervalued

Now 20% undervalued after recent price drop

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Now 20% undervalued

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022)

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold US$731k worth of stock

Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022)

Now 21% undervalued

Insider recently sold US$301k worth of stock

Senior VP recently sold US$890k worth of stock

First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022)

An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC).

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold US$137k worth of stock

Executive VP & Chief Strategy Officer recently sold US$501k worth of stock

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023

AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion.

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer

AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion.

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion.

Third quarter 2022 earnings released: EPS: US$1.95 (vs US$1.42 in 3Q 2021)

AmerisourceBergen Corporation Reports Goodwill Impairment for the Three Months Ended June 30, 2022

AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products

AmerisourceBergen Corporation to Report Q3, 2022 Results on Aug 03, 2022

AmerisourceBergen Corporation (NYSE:ABC) announces an Equity Buyback for $1,000 million worth of its shares.

AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide

Senior VP recently sold US$783k worth of stock

An unknown buyer acquired 2.9% stake in AmerisourceBergen Corporation (NYSE:ABC) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $900 million.

Second quarter 2022 earnings released: EPS: US$2.62 (vs US$2.12 in 2Q 2021)

Amerisourcebergen Corporation Corporation Declares Quarterly Cash Dividend, Payable on May 31, 2022

Insufficient new directors

AmerisourceBergen Launches $150 Million Venture Capital Fund

AmerisourceBergen Corporation to Report Q2, 2022 Results on May 04, 2022

Insider recently sold US$1.0m worth of stock

AmerisourceBergen, Cardinal Health and McKesson Approve Opioid Settlement Agreement

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

AmerisourceBergen Corporation Declares a Quarterly Cash Dividend, Payable on February 28, 2022

AmerisourceBergen Corporation, Annual General Meeting, Mar 10, 2022

AmerisourceBergen Corporation, Annual General Meeting, Mar 10, 2022

AmerisourceBergen and TrakCel Launch Integrated Platform to Support Cell and Gene Therapies

AmerisourceBergen Corporation Debuts RFID Tagging Service, Allowing Customers Nationwide to Purchase Pre-Tagged Product That Is Also Technology Agnostic

Insider recently sold US$2.0m worth of stock